Clinical Trial Update: Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid Malignancies [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial evaluating donor natural killer cells and donor stem cell transplant in high-risk myeloid malignancies; completed with results posted i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
• Acute Myeloid Leukemia in Remission
• Blast Phase Chronic Myeloid Leukemia Bcr-abl1-positive
• Blasts Under 20 Percent of Bone Marrow Nucleated Cells
• Blasts Under 20 Percent of Peripheral Blood White Cells
• Chronic Myeloid Leukemia Bcr-abl1 Positive in Accelerated Phase
• Erythroid Leukemia
• High-risk Myelodysplastic Syndrome
• Megakaryoblastic Leukemia
• Myelodysplastic Syndrome
• Myelogenous Leukemia Bcr-abl1 Positive
• Therapy-related Acute Myeloid Leukemia
• Therapy-related Myelodysplastic Syndrome

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Erythroid Leukemia | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2023-11-07